{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:37:41Z","timestamp":1793230661745,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017006","name":"Abramson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.blre.2025.101358","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:11:20Z","timestamp":1765901480000},"page":"101358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["CAR-T for all? Barriers, facilitators, and interventions to commercial CAR T-cell therapy access"],"prefix":"10.1016","volume":"76","author":[{"given":"Sofia","family":"Kaparis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khashayar","family":"Eshaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Paruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalpa","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen E.","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.blre.2025.101358_bb0005","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300213","article-title":"CAR T-cell immunotherapy in minority patients with lymphoma","volume":"3","author":"Ghilardi","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.blre.2025.101358_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101136","article-title":"Access to CAR T-cell therapy: focus on diversity, equity and inclusion","volume":"63","author":"Odstrcil","year":"2024","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101358_bb0015","series-title":"CAR T cells: engineering patients\u2019 immune cells to treat their cancers","author":"National Cancer Institute","year":"2025"},{"key":"10.1016\/j.blre.2025.101358_bb0020","author":"FDA-approved CAR T-cell Therapies"},{"key":"10.1016\/j.blre.2025.101358_bb0025","series-title":"YESCARTA","author":"US Food & Drug Administration","year":"2023"},{"key":"10.1016\/j.blre.2025.101358_bb0030","series-title":"CARVYKTI","author":"US Food & Drug Administration","year":"2022"},{"key":"10.1016\/j.blre.2025.101358_bb0035","series-title":"ABECMA","author":"US Food & Drug Administration","year":"2021"},{"key":"10.1016\/j.blre.2025.101358_bb0040","series-title":"BREYANZI","author":"US Food & Drug Administration","year":"2021"},{"key":"10.1016\/j.blre.2025.101358_bb0045","series-title":"KYMRIAH","author":"US Food & Drug Administration","year":"2017"},{"key":"10.1016\/j.blre.2025.101358_bb0050","series-title":"AUCTAZYL","author":"US Food & Drug Administration","year":"2024"},{"issue":"7","key":"10.1016\/j.blre.2025.101358_bb0055","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.blre.2025.101358_bb0060","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jtct.2024.04.017","article-title":"Chimeric antigen receptor T-cell access in patients with relapsed\/refractory large B-cell lymphoma: association of access with social determinants of health and travel time to treatment centers","volume":"30","author":"Ahmed","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"23","key":"10.1016\/j.blre.2025.101358_bb0065","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1002\/cam4.4797","article-title":"Demographic differences among patients treated with chimeric antigen receptor T-cell therapy in the United States","volume":"11","author":"Emole","year":"2022","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.blre.2025.101358_bb0070","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jtct.2024.06.011","article-title":"CAR-T therapy for all: Addressing the access gap","volume":"30","author":"Ruella","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.blre.2025.101358_bb0075","series-title":"Updates to race\/ethnicity standards for our nation","author":"US Census Bureau","year":"2024"},{"issue":"2","key":"10.1016\/j.blre.2025.101358_bb0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.clml.2024.09.010","article-title":"Sociodemographic factors influencing access to chimeric antigen T-cell receptor therapy for patients with non-Hodgkin lymphoma","volume":"25","author":"Khare","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.blre.2025.101358_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bict.2025.100007","article-title":"Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma","volume":"1","author":"Paruzzo","year":"2025","journal-title":"Blood Immunol Cell Ther"},{"issue":"11","key":"10.1016\/j.blre.2025.101358_bb0090","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/s41409-025-02693-0","article-title":"The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"60","author":"O\u2019Connor","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.blre.2025.101358_bb0095","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1182\/bloodadvances.2022007676","article-title":"The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes","volume":"6","author":"Faruqi","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2025.101358_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.12.454","article-title":"Neighborhood socioeconomic disadvantage and distance from treatment center do not impact survival outcomes of patients with non-Hodgkin\u2019s lymphoma (NHL) and multiple myeloma (MM) treated with CAR T-cell therapies","volume":"30","author":"Mian","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.blre.2025.101358_bb0105","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2025.101358_bb0110","first-page":"14","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.blre.2025.101358_bb0115","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.bbmt.2020.04.008","article-title":"Chimeric antigen receptor T cell therapy during the COVID-19 pandemic","volume":"26","author":"Bachanova","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2025.101358_bb0120","first-page":"163","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceut Med"},{"issue":"7","key":"10.1016\/j.blre.2025.101358_bb0125","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jtct.2023.04.003","article-title":"Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"29","author":"Hoffmann","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.blre.2025.101358_bb0130","first-page":"43","article-title":"Embracing myeloma chimeric antigen receptor-T: from scientific design to clinical impact","author":"Hosoya","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"10.1016\/j.blre.2025.101358_bb0135","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2217\/imt-2022-0037","article-title":"Barriers and solutions to improve access for chimeric antigen receptor therapies","volume":"14","author":"Kamal-Bahl","year":"2022","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.blre.2025.101358_bb0140","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1007\/s12325-021-01839-y","article-title":"Travel-related economic burden of chimeric antigen receptor T cell therapy administration by site of care","volume":"38","author":"Snyder","year":"2021","journal-title":"Adv Ther"},{"issue":"13","key":"10.1016\/j.blre.2025.101358_bb0145","first-page":"253","article-title":"Improving outcomes and mitigating costs associated with CAR T-cell therapy","volume":"27","author":"Borgert","year":"2021","journal-title":"Am J Manag Care"},{"issue":"4","key":"10.1016\/j.blre.2025.101358_bb0150","article-title":"Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas","volume":"8","author":"Di","year":"2024","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.blre.2025.101358_bb0155","first-page":"1","article-title":"Expanding access to chimeric antigen receptor T-cell therapies: challenges and opportunities","volume":"40","author":"Kansagra","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3\u20134","key":"10.1016\/j.blre.2025.101358_bb0160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/j.seminoncol.2024.02.001","article-title":"CAR T-cell therapy: a collaboration between authorized treatment centers and community oncologists","volume":"51","author":"Bishop","year":"2024","journal-title":"Semin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2025.101358_bb0165","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-cell therapies: barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"10.1016\/j.blre.2025.101358_bb0170","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1370\/afm.2632","article-title":"Discrimination and medical mistrust in a racially and ethnically diverse sample of California adults","volume":"19","author":"Bazargan","year":"2021","journal-title":"Ann Fam Med"},{"issue":"9","key":"10.1016\/j.blre.2025.101358_bb0175","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cncr.32755","article-title":"Bias and stereotyping among research and clinical professionals: perspectives on minority recruitment for oncology clinical trials","volume":"126","author":"Niranjan","year":"2020","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.blre.2025.101358_bb0180","doi-asserted-by":"crossref","first-page":"925.e1","DOI":"10.1016\/j.jtct.2024.05.011","article-title":"TACTUM: trends in access to cellular therapies in multiple myeloma, perspectives of treating versus referring physicians","volume":"30","author":"Atallah","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.blre.2025.101358_bb0185","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2217\/imt-2020-0118","article-title":"Perceptions of community hematologists\/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma","volume":"12","author":"Gajra","year":"2020","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.blre.2025.101358_bb0190","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/bloodadvances.2024014171","article-title":"Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network","volume":"9","author":"Battiwalla","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101358_bb0195","article-title":"T challenges: enhancing collaboration for patient care","author":"Shaw","year":"2024","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.blre.2025.101358_bb0200","series-title":"Poster session presented at: Association of Cancer Care Centers 50th annual meeting and cancer center business summit; February 28-March 1","article-title":"Bringing CAR T education and awareness to the hematology\/oncology community","author":"Machado","year":"2024"},{"issue":"1","key":"10.1016\/j.blre.2025.101358_bb0205","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jtct.2023.10.019","article-title":"If they RECUR, you should refer: a community oncologist patient ID roundtable summary","volume":"30","author":"Riedell","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"18","key":"10.1016\/j.blre.2025.101358_bb0210","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1182\/bloodadvances.2024015634","article-title":"Inequalities in CAR T-cell therapy access for US patients with relapsed\/refractory DLBCL: a SEER-medicare data analysis","volume":"9","author":"Chung","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101358_bb0215","series-title":"Directory of CAR T-cell therapy centers","author":"Blood & Marrow Transplant Information Network","year":"2024"},{"key":"10.1016\/j.blre.2025.101358_bb0220","author":"Foundation for the Accreditation of Cellular Therapy"},{"key":"10.1016\/j.blre.2025.101358_bb0225","series-title":"Transplant center locations","author":"National Marrow Donor Program","year":"2024"},{"key":"10.1016\/j.blre.2025.101358_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1206715","article-title":"\u201cWaitlist mortality\u201d is high for myeloma patients with limited access to BCMA therapy","volume":"13","author":"Ahmed","year":"2023","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.blre.2025.101358_bb0235","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11899-021-00635-3","article-title":"Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments","volume":"16","author":"Geethakumari","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"10.1016\/j.blre.2025.101358_bb0240","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/bloodadvances.2024015013","article-title":"Receiving CAR T-cells gets faster, but not for all in need","volume":"9","author":"Ramos","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101358_bb0245","series-title":"Health coverage by race and ethnicity, 2010\u20132023","author":"Artiga","year":"2024"},{"key":"10.1016\/j.blre.2025.101358_bb0250","series-title":"April 2024 Medicaid & CHIP enrollment data highlights","author":"Medicaid","year":"2024"},{"key":"10.1016\/j.blre.2025.101358_bb0255","series-title":"Distribution of the nonelderly with Medicaid by race\/ethnicity","author":"Kaiser Family Foundation","year":"2022"},{"issue":"11","key":"10.1016\/j.blre.2025.101358_bb0260","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jtct.2023.08.007","article-title":"Assessing Medicaid coverage for hematopoietic cell transplantation and chimeric antigen receptor T cell therapy: a project from the American Society for Transplantation and Cellular Therapy and the National Marrow Donor Program ACCESS initiative","volume":"29","author":"Auletta","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.blre.2025.101358_bb0265","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.ymthe.2022.08.009","article-title":"Assessing the state of Medicaid coverage for gene and cell therapies","volume":"30","author":"Berry","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2025.101358_bb0270","series-title":"Access to transformative therapies for Medicaid enrollees","author":"Polaris","year":"2025"},{"issue":"3","key":"10.1016\/j.blre.2025.101358_bb0275","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbmt.2019.12.093","volume":"26","author":"Bachier","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.blre.2025.101358_bb0280","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.clml.2022.04.012","article-title":"Outcomes of Tisagenlecleucel in lymphoma patients with predominant Management in an Ambulatory Setting","volume":"22","author":"Nasta","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.blre.2025.101358_bb0285","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1007\/s12325-021-01838-z","article-title":"Access to chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma","volume":"38","author":"Snyder","year":"2021","journal-title":"Adv Ther"},{"issue":"19","key":"10.1016\/j.blre.2025.101358_bb0290","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.3390\/cancers17193216","article-title":"Eliminating REMS for CAR T-cell therapies: an opportunity to improve access","volume":"17","author":"Orosco-Ttamina","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2025.101358_bb0295","article-title":"High cost of chimeric antigen receptor T-cells: challenges and solutions","volume":"43","author":"Cliff","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.blre.2025.101358_bb0300","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/j.seminhematol.2023.01.001","article-title":"Place of care manufacturing of chimeric antigen receptor cells: opportunities and challenges","volume":"60","author":"Orentas","year":"2023","journal-title":"Semin Hematol"},{"issue":"12","key":"10.1016\/j.blre.2025.101358_bb0305","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.ccell.2023.10.002","article-title":"Bringing CAR T cell therapy trials to underserved populations","volume":"41","author":"Badr","year":"2023","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.blre.2025.101358_bb0310","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1002\/cncr.33779","article-title":"Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphoma","volume":"127","author":"Hu","year":"2021","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.blre.2025.101358_bb0315","first-page":"3539","article-title":"History and principles of patient navigation","volume":"117","author":"Freeman","year":"2011","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.blre.2025.101358_bb0320","first-page":"565","article-title":"Patient navigation across the cancer care continuum: an overview of systematic reviews and emerging literature","volume":"73","author":"Chan","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.blre.2025.101358_bb0325","first-page":"528","article-title":"Nursing considerations in navigating patients receiving CAR T-cell therapy","volume":"28","author":"Ferguson","year":"2024","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.blre.2025.101358_bb0330","first-page":"13","article-title":"No oncology patient left behind: challenges and solutions in rural radiation oncology","author":"Kenamond","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"8","key":"10.1016\/j.blre.2025.101358_bb0335","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41409-022-01711-9","article-title":"Peer support in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT): a qualitative study","volume":"57","author":"Amonoo","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2025.101358_bb0340","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s13187-019-01506-5","article-title":"Information needs for treatment decision-making of hematopoietic cell transplant patients 65 years or older and caregivers","volume":"35","author":"Foster","year":"2020","journal-title":"J Cancer Educ"},{"key":"10.1016\/j.blre.2025.101358_bb0345","series-title":"Road to recovery","author":"American Cancer Society","year":"2025"},{"key":"10.1016\/j.blre.2025.101358_bb0350","series-title":"Hope lodge","author":"American Cancer Society","year":"2025"},{"issue":"12","key":"10.1016\/j.blre.2025.101358_bb0355","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jtct.2022.09.020","article-title":"The ASTCT-NMDP ACCESS initiative: a collaboration to address and sustain equal outcomes for all across the hematopoietic cell transplantation and cellular therapy ecosystem","volume":"28","author":"Auletta","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.blre.2025.101358_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.09.041","article-title":"Understanding diversity: an ASTCT-NMDP ACCESS initiative survey of the hematopoietic cell transplant and cellular therapy workforce in the United States","author":"Pereda Ginocchio","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.blre.2025.101358_bb0365","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jtct.2024.09.004","article-title":"Proceedings of the 2024 third annual ASTCT-NMDP ACCESS initiative workshop","volume":"30","author":"Auletta","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.blre.2025.101358_bb0370","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jtct.2025.08.027","article-title":"Proceedings from the second reimagining caregiver workshop: addressing caregiver requirements for hematopoietic cell transplant","volume":"31","author":"Preussler","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.blre.2025.101358_bb0375","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jtct.2025.04.006","article-title":"Proceedings from the reimagining caregiver workshop: addressing caregiver requirements for hematopoietic cell transplant","volume":"31","author":"Preussler","year":"2025","journal-title":"Transplant Cell Ther"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25001031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25001031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:12:05Z","timestamp":1788221525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25001031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":75,"alternative-id":["S0268960X25001031"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101358","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T for all? Barriers, facilitators, and interventions to commercial CAR T-cell therapy access","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101358"}}